{"product_id":"pharmaceutical-amorphous-solid-dispersions-isbn-9781118455203","title":"Pharmaceutical Amorphous Solid Dispersions","description":"Providing a roadmap from early to late stages of drug development, this book overviews amorphous solid dispersion technology – a leading platform to deliver poorly water soluble drugs, a major hurdle in today’s pharmaceutical industry.\u003cbr\u003e \u003cbr\u003e • Helps readers understand amorphous solid dispersions and apply techniques to particular pharmaceutical systems\u003cbr\u003e • Covers physical and chemical properties, screening, scale-up, formulation, drug product manufacture, intellectual property, and regulatory considerations\u003cbr\u003e • Has an appendix with structure and property information for polymers commonly used in drug development and with marketed drugs developed using the amorphous sold dispersion approach\u003cbr\u003e • Addresses global regulatory issues including USA regulations, ICH guidelines, and patent concerns around the world Contents\u003cbr\u003e\u003cbr\u003eContributors\u003cbr\u003e\u003cbr\u003ePreface\u003cbr\u003e\u003cbr\u003e\u003cb\u003eChapter 1: Introduction to Amorphous Solid Dispersions\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eGeorge Zografi and Ann Newman\u003cbr\u003e\u003cbr\u003e\u003c\/i\u003e\u003cb\u003eChapter 2: Polymers and Surfactants\u003c\/b\u003e\u003cbr\u003e\u003ci\u003ePadma Narayan, William W. Porter III, Meinolf Brackhagen, and Christopher Tucker\u003cbr\u003e\u003cbr\u003e\u003c\/i\u003e\u003cb\u003eChapter 3: Amorphous Solid Dispersion Screening\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eAnn Newman\u003cbr\u003e\u003cbr\u003e\u003c\/i\u003e\u003cb\u003eChapter 4: Solid state Characterization of Amorphous Dispersions\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eFrederick G. Vogt\u003cbr\u003e\u003cbr\u003e\u003c\/i\u003e\u003cb\u003eChapter 5: Physical Stability and Crystallization Inhibition\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eLynne S. Taylor\u003cbr\u003e\u003cbr\u003e\u003c\/i\u003e\u003cb\u003eChapter 6: Solubility and Dissolution Considerations for Amorphous Solid Dispersions\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eGrace A. Ilevbare, Wei Xu, Christopher T. John, James Ormes, Jesse Kuiper, Allen C. \u003c\/i\u003e\u003ci\u003eTempleton, and Annette Bak\u003cbr\u003e\u003cbr\u003e\u003c\/i\u003e\u003cb\u003eChapter 7: Translational Development of Amorphous Dispersions\u003c\/b\u003e\u003cbr\u003e\u003ci\u003ePatrick Connelly, Brian Patrick Quinn, Steve Johnston, Philip Bransford, Praveen Mudunuri, Andrey \u003c\/i\u003e\u003ci\u003ePeresypkin, Majed Fawaz, Setu Roday, Anuj Kuldipkumar, Hong-Ren Wang, Phillip \u003c\/i\u003e\u003ci\u003eSnyder, Jeff Katstra, Tapan Sanghvi, Bill Rowe, and Patricia Hurter\u003cbr\u003e\u003cbr\u003e\u003c\/i\u003e\u003cb\u003eChapter 8: Preclinical and Clinical Studies\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eMarcus E. Brewster, Geert Verreck, Jan Bevernage, Joachim Brouwers, Guy Van den Mooter, \u003c\/i\u003e\u003ci\u003eand Patrick Augustijns\u003cbr\u003e\u003cbr\u003e\u003c\/i\u003e\u003cb\u003eChapter 9: Spray-Drying and Scale-Up\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eDaniel E. Dobry, Dana M. Settell, and John M. Baumann\u003cbr\u003e\u003cbr\u003e\u003c\/i\u003e\u003cb\u003eChapter 10: Hot Melt Extrusion of Amorphous Solid Dispersions\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eKieran Crowley and Andreas Gryczke\u003cbr\u003e\u003cbr\u003e\u003c\/i\u003e\u003cb\u003eChapter 11: Formulation Development of Amorphous Dispersions\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eTapan Sanghvi, Jeff Katstra, Brian Patrick Quinn, Hayden Thomas, and Patricia Hurter\u003cbr\u003e\u003cbr\u003e\u003c\/i\u003e\u003cb\u003eChapter 12: Scientific and Regulatory Considerations in Product Development\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eAbhay Gupta, Ziyaur Rahmna, and Manssor A. Khan\u003cbr\u003e\u003cbr\u003e\u003c\/i\u003e\u003cb\u003eChapter 13: Chapter Patenting Amorphous Solid Dispersions of Pharmaceuticals\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eJeffry A. Lindeman\u003c\/i\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eChapter 14: Monographs on Polymers and Surfactants\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eXia Lu, Robert Wenslow, and Ann Newman\u003cbr\u003e\u003cbr\u003e\u003c\/i\u003eAppendix 1\u003cbr\u003e\u003ci\u003eXia Lu, Robert Wenslow, and Ann Newman\u003cbr\u003e\u003cbr\u003e\u003c\/i\u003eAppendix 2: Marketed Products\u003cbr\u003e\u003ci\u003eAnn Newman\u003c\/i\u003e \u003cb\u003eAnn Newman\u003c\/b\u003e is a pharmaceutical consultant with Seventh Street Development Group, where she provides consulting, training, and webcast services on solid-state pharmaceutics and pharmaceutical development. She is also an Adjunct Professor and Lecturer in the Department of Industrial and Physical Pharmacy at Purdue University. A senior pharmaceutical scientist with demonstrated scientific and leadership expertise in the pharmaceutical industry, Dr. Newman has over 25 years of large pharma and contract research experience.  \u003cp\u003e\u003cb\u003eA roadmap to enhance and maximize drug solubility and bioavailability\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eWith an increasing number of poorly soluble or difficult to crystallize drugs entering development, new formulation strategies are required to achieve sufficient bioavailability. Amorphous solid dispersions are an option receiving increased attention in recent years, because they can improve dissolution rates and increase solubility characteristics of drug compounds.\u003cbr\u003e \u003cbr\u003e This book highlights and discusses the advances in developing pharmaceutical amorphous solid dispersions. Chapters, written by contributing authors on the frontlines of R \u0026amp; D, provide a roadmap from early to late stages of drug development. They cover topics that include: physical and chemical properties, screening, scale-up, formulation, drug product manufacture, intellectual property, and regulatory considerations.\u003cbr\u003e \u003cbr\u003e Pharmaceutical scientists using this book as a guide for formulating their drugs benefit from a number of features, including:\u003c\/p\u003e \u003cp\u003e•     A comprehensive overview of the amorphous solid dispersion technology, which is a leading technology platform to deliver poorly water soluble drugs – a major hurdle in today’s pharmaceutical industry\u003c\/p\u003e \u003cp\u003e•     How to apply amorphous solid dispersions techniques to particular pharmaceutical systems\u003c\/p\u003e \u003cp\u003e•     An appendix with structure and property information for polymers commonly used in drug development and with marketed drugs developed using the amorphous sold dispersion approach\u003c\/p\u003e •     Global regulatory issues including USA regulations, ICH guidelines, and patent concerns around the world","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989771829477,"sku":"NP9781118455203","price":193.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118455203.jpg?v=1761785419","url":"https:\/\/k12savings.com\/products\/pharmaceutical-amorphous-solid-dispersions-isbn-9781118455203","provider":"K12savings","version":"1.0","type":"link"}